Apomorphine: A sublingual dopamine agonist for the treatment of erectile dysfunction

Formulary

Volumn 35, Issue 7, 2000, Pages 573-579

  Feret, Brett ^a  

^a HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG MARKETING; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; MALE; NAUSEA; PARKINSON DISEASE; SEXUAL INTERCOURSE;

EID: 0033940013     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993;270:83-90.
2. Wierman M. Advances in the diagnosis and management of impotence. Dis Mon 1999;45:6-20.
3. Courty E, Durif F, Zenut M, et al. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol 1997;20:140-7.
4. Lal S, Tesfaye Y, Thavundayil JX, et al. Apomorphine: Clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:329-39.
5. Paick J-S, Lee SW. The neural mechanism of apomorphine-induced erection: An experimental study by comparison with electrostimulation-induced erection in the rat model. J Urol 1994;152:2125-8.
6. Melis MR, Argiolas A, Gessa GL. Apomorphine-induced penile erection and yawning: Site of action in brain. Brain Res 1987; 415:98-104.
7. Meinhardt W, Kropman RF, Vermeij P. Comparative tolerability and efficacy of treatments for impotence. Drug Saf 1999; 20:133-46.
8. Heaton JPW, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:200-6.
9. Danjou P, Alexandre L, Warot D, et al. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 1988;26:733-9.
10. Segraves RT, Bari M, Segraves K, Spirnak P. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol 1991;145:1174-5.
11. Manabe K, Heaton JPW, Morales A, et al. Time course for erections with apomorphine and sexual stimulation is similar but more rapid than with ICI in human subjects due to recruitment of extrapenile vessels. J Urol 1997;157(4 Suppl):184. Abstract 714.
12. Durif F, Paire M, Deffond D, et al. Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. Clin Neuropharmacol 1993;16:157-66.
13. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-8.
14. Kaul PN, Brochmann-Hanssen E, Way EL. Biological disposition of apomorphine III: Kinetics of metabolism of apomorphine and role of the liver in its biotransformation. J Pharm Sci 1961;50:248-51.
15. Padma-Nathan H. Fromm-Freeck S, Ruff DD, et al, and the Apomorphine SL Study Group. Efficacy and safety of apomorphine SL vs placebo for male erectile dysfunction. J Urol 1998;159(5 Suppl):241. Abstract 920.
16. Padma-Nathan H, Auerbach S, Lewis R, et al, and the Apomorphine SL Study Group. Efficacy and safety of apomorphine SL vs placebo for male erectile dysfunction. J Urol 1999;161(4 Suppl):214. Abstract 821.
17. Lewis R, Agre K, Fromm S, Ruff D, and the Apomorphine SL Study Group. Efficacy of apomorphine SL vs placebo for erectile dysfunction in patients with hypertension. J Urol 1999;161(4 Suppl):214. Abstract 822.
18. Dula E, Buttler S, Perdok R, Agre K. Efficacy and safety of apomorphine SL vs placebo for erectile dysfunction in patients with coronary artery disease. J Urol 2000; 163(4 Suppl). Abstract 889.
19. New therapies in phase III trials. Ninety-fourth American Urological Association Meeting. Available at:www.medscape.com/ medscape/urology/journal/1999/v01n03/ mu0.../mu0603.01.htm.
20. Personal communication from TAP Pharmaceuticals, Deerfield, IL; April 2000.
21. Caverject (alprostadil for injection) package insert. Kalamazoo, MI: Pharmacia & Upjohn; February 1999.
22. MUSE (alprostadil) package insert. Mountain View, CA: Vivus, Inc; February 1998.
23. Viagra (sildenafil citrate) package insert. New York, NY: Pfizer Labs; June 1999.